F&G Annuities & Life cleared a modest bar in the third quarter, reporting adjusted earnings of $0.74 per share against a $0.66 consensus, a 12.1% beat. Revenue of $1.131 billion topped the $731.0 million estimate by 54.7%. The beat does not change the larger picture: earnings fell 39.3% year over year and revenue declined 33.2%. Adjusted return on equity, excluding AOCI, slipped to 6.7%. The central tension is that F&G is selling more of its core product than ever, while the earnings that business produces for shareholders keep shrinking.

The quality of the quarter deserves scrutiny from two directions. GAAP net earnings jumped to $736 million, or $5.48 per share, from $0.85 a year ago. Almost all of that gain came from $648 million of favorable mark-to-market effects, including a $297 million actuarial reserve release from the annual assumption review. That review also lifted book value per share excluding AOCI by $5.44 in one quarter, to $51.37. Including AOCI, book value per share fell to $31.48 from $33.27. Revenue is similarly noisy. It moves with life-contingent PRT premiums and recognized gains, so the large revenue surprise says little about operating momentum. On the adjusted line, the drag was real but partly cyclical. Alternative investments earned $60 million, or $0.46 per share, below management's roughly 12% long-term expectation. That shortfall was wider than the $0.38 gap a year earlier. Beyond the alts shortfall, management cited several structural pressures on product margin:

• the loss of F&G Life Re (Bermuda) earnings after its sale;
• lower surrender charge income;
• higher other liability costs.

The operating story has genuine strengths. Core retail sales hit a record $2.1 billion, up 24% year over year and 17% sequentially. F&G's fixed indexed annuity sales were up 12% year to date, while the industry was down 6%. Sales growth was paired with efficiency gains:

• The fixed income yield rose to 4.98% from 4.77% in the first quarter.
• The operating expense ratio improved to 46 basis points, close to the 45-basis-point target set for year-end 2027.
• Adjusted earnings rose sequentially from $0.65 in the second quarter.
• PRT mortality improved by roughly $10 million per quarter, reversing the second quarter's softness.

Against that, headline growth is being deliberately sacrificed. Gross sales fell to $3.0 billion from $4.2 billion as multiyear guaranteed annuity volume collapsed to $73 million from $969 million on pricing discipline. Net sales were halved to $1.4 billion. With roughly two-thirds of FIA sales ceded through flow reinsurance, retained AUM of $56.2 billion is actually slightly below a year ago. One analyst pressed management on exactly that point. The fee-based, capital-light pivot management is promoting is real, but it means record sales do not translate cleanly into spread earnings.

The forward signals leaned negative:

• Full-year PRT sales guidance was cut to $1.0-1.5 billion from $1.5-2.0 billion, with only about $700 million written through nine months.
• The annualized alts return slid to about 5%, from 6% in the second quarter and 8.3% in the first, as equity residuals marked negative.
• Management now cites a flat 12% long-term alts assumption rather than a 12-14% range.
• The assumption review adds about $6 million per quarter of after-tax DAC amortization through 2027 because surrenders are elevated. Management expects surrenders to stay high after the 10-year yield rose 83 basis points in the quarter.

Bears have legitimate ammunition on capital as well. Moody's affirmed its ratings but moved to a negative outlook. Management now describes risk-based capital as "at" roughly 400%, rather than above it. It also flagged more than $500 million of regulatory capital headwinds this year, plus pending NAIC charges on reinsurance to non-reciprocal jurisdictions; a Cayman affiliate holds 80% of the PRT business. Offsets include a new $100 million buyback authorization, an active strategic-alternatives process for Peak Altitude, potential benefits from early VM-22 adoption, and management's expectation of a better fourth-quarter alts return.

The market has already priced in much of this skepticism. Shares at $21.68 are down 22.8% since the open after the August report. They sit 15.5% below the 200-day moving average of $25.67 and well under even AOCI-inclusive book value. Investor sentiment improved only marginally, from -0.119 to -0.106, and remains negative. That small move fits a quarter with a consensus beat but no clear turn in returns.

The bottom line is that F&G delivered a cleaner sequential quarter and a franchise that is clearly winning retail share. However, the metrics that drive valuation all moved the wrong way:

• return on equity;
• alternative investment yields;
• PRT volume;
• capital headroom;
• the rating outlook.

The reserve-driven book value jump flatters the balance sheet without fixing earnings power. Until alts normalize and capital concerns ease, the discount to book is likely to look justified to skeptics rather than compelling.